An anti-β-amyloid vaccine for treating cognitive deficits in a mouse model of Down syndrome

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Belichenko, Pavel V ^a   Madani, Rime ^b   Rey Bellet, Lorianne ^b   Pihlgren, Maria ^b   Becker, Ann ^a   Plassard, Adeline ^b   Vuillermot, Stephanie ^b   Giriens, Valérie ^b   Nosheny, Rachel L ^a   Kleschevnikov, Alexander M ^a   Valletta, Janice S ^a   Bengtsson, Sara K S ^a   Linke, Gordon R ^a   Maloney, Michael T ^c   Hickman, David T ^b   Reis, Pedro ^b   Granet, Anne ^b   Mlaki, Dorin ^b   Lope Deber, Maria Pilar ^b   Do, Long ^a   Singhal, Nishant ^a   Masliah, Eliezer ^a   Pearn, Matthew L ^a   Pfeifer, Andrea ^b   Muhs, Andreas ^b   Mobley, William C ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AC IMMUNE SA   (Switzerland)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-15] ANTIBODY; AMYLOID PRECURSOR PROTEIN; IMMUNOGLOBULIN G ANTIBODY; LIPOSOME; PEPTIDE VACCINE; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; ANTIBODY; BIOLOGICAL MARKER; VACCINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APP GENE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHOLINERGIC NERVE CELL; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DIPLOIDY; DOWN SYNDROME; FEAR CONDITIONING TEST; MALE; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PROTEIN BINDING; VACCINATION; ANIMAL; ANIMAL BEHAVIOR; ATROPHY; BLEEDING; BRAIN; COGNITION DISORDERS; COMPLICATION; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INFLAMMATION; MEMORY; METABOLISM; NEWBORN; PATHOLOGY; SEPTUM NUCLEUS; TRANSGENIC MOUSE;

AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES; ATROPHY; BEHAVIOR, ANIMAL; BIOMARKERS; BRAIN; CHOLINERGIC NEURONS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOWN SYNDROME; GENE EXPRESSION REGULATION; HEMORRHAGE; INFLAMMATION; MALE; MEMORY; MICE, TRANSGENIC; SEPTAL NUCLEI; VACCINATION; VACCINES;

EID: 84962159014     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152471     Document Type: Article

References (59)

1. Antonarakis SE, Reymond A, Lyle R, Deutsch S, Dermitzakis ET. Chromosome 21 and Down syndrome: the post-sequence era. Cold Spring Harb Symp Quant Biol 2003;68:425-30. PMID: 15338645
2. Moncaster JA, Pineda R, Moir RD, Lu S, Burton MA, Ghosh JG, et al. Alzheimer's disease amyloidbeta links lens and brain pathology in Down syndrome. PLoS One 2010;5(5):e10659. doi: 10.1371/journal.pone.0010659 PMID: 20502642
3. Sherman SL, Allen EG, Bean LH, Freeman SB. Epidemiology of Down syndrome. Ment Retard Dev Disabil Res Rev 2007;13(3):221-7. PMID: 17910090
4. Sturgeon X, Gardiner KJ. Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mamm Genome 2011 Jun; 22(5-6):261-71. doi: 10.1007/s00335-011-9321-y PMID: 21400203
5. Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 1985 Mar; 17(3):278-82. PMID: 3158266
6. Coppus A, Evenhuis H, Verberne GJ, Visser F, van GP, Eikelenboom P, et al. Dementia and mortality in persons with Down's syndrome. J Intellect Disabil Res 2006 Oct; 50(Pt 10):768-77. PMID: 16961706
7. Hartley D, Blumenthal T, Carrillo M, Di Paolo G, Esralew L, Gardiner K, et al. Down syndrome and Alzheimer's disease: Common pathways, common goals. Alzheimers Dement 2014 Dec. 12.
8. Lai F, Williams RS. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 1989 Aug; 46(8):849-53. PMID: 2527024
9. Zigman WB, Lott IT. Alzheimer's disease in Down syndrome: Neurobiology and risk. Ment Retard Dev Disabil Res Rev 2007;13(3):237-46. PMID: 17910085
10. Schupf N, Sergievsky GH. Genetic and host factors for dementia in Down's syndrome. Br J Psychiatry 2002 May; 180:405-10. PMID: 11983636
11. Stanton LR, Coetzee RH. Down's syndrome and dementia. Advances in Psychiatric Treatment 2004;10:50-8.
12. Cabrejo L, Guyant-Marechal L, Laquerriere A, Vercelletto M, De la FF, Thomas-Anterion C, et al. Phenotype associated with APP duplication in five families. Brain 2006 Nov; 129(Pt 11):2966-76. PMID: 16959815
13. Sleegers K, Lambert JC, Bertram L, Cruts M, Amouyel P, Van BC. The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet 2010 Feb; 26(2):84-93. doi: 10.1016/j.tig.2009.12.004 PMID: 20080314
14. Glasson EJ, Sullivan SG, Hussain R, Petterson BA, Montgomery PD, Bittles AH. The changing survival profile of people with Down's syndrome: implications for genetic counselling. Clin Genet 2002 Nov; 62(5):390-3. PMID: 12431254
15. Bittles AH, Bower C, Hussain R, Glasson EJ. The four ages of Down syndrome. Eur J Public Health 2007 Apr; 17(2):221-5. PMID: 16857692
16. Prasher VP. Down's syndrome, longevity, and Alzheimer's disease. Br J Psychiatry 1993 May; 162:711.
17. Prasher VP. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. Int J Geriatr Psychiatry 2004 Jun; 19(6):509-15. PMID: 15211527
18. Head E, Silverman W, Patterson D, Lott IT. Aging and down syndrome. Curr Gerontol Geriatr Res 2012;2012:412536. doi: 10.1155/2012/412536 PMID: 22844278
19. Rafii MS. The pulse of drug development for Alzheimer's disease. Rev Recent Clin Trials 2010 Jan; 5(1):57-62. PMID: 20205688
20. Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 2006 May; 6(5):404-16. PMID: 16639431
21. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003 May 22;38(4):547-54. PMID: 12765607
22. Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron 2013 Dec. 18;80(6):1347-58. doi: 10.1016/j.neuron. 2013.12.003 PMID: 24360540
23. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013 Feb; 12(2):207-16. doi: 10.1016/S1474-4422 (12) 70291-0 PMID: 23332364
24. Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, et al. Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease. Sci Transl Med 2014 Mar. 5;6(226):226ra30. doi: 10.1126/scitranslmed.3007901 PMID: 24598588
25. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012 Aug. 30;367(9):795-804. doi: 10.1056/NEJMoa1202753 PMID: 22784036
26. Ryman DC, costa-Baena N, Aisen PS, Bird T, Danek A, Fox NC, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 2014 Jul. 15;83(3):253-60. doi: 10.1212/WNL.0000000000000596 PMID: 24928124
27. Davisson MT, Schmidt C, Reeves RH, Irving NG, Akeson EC, Harris BS, et al. Segmental trisomy as a mouse model for Down syndrome. Prog Clin Biol Res 1993;384:117-33. PMID: 8115398
28. Hunter CL, Bimonte-Nelson HA, Nelson M, Eckman CB, Granholm AC. Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice: effects of estrogen. Neurobiol Aging 2004 Aug; 25(7):873-84. PMID: 15212841
29. Holtzman DM, Santucci D, Kilbridge J, Chua-Couzens J, Fontana DJ, Daniels SE, et al. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci U S A 1996 Nov. 12;93(23):13333-8. PMID: 8917591
30. Belichenko PV, Masliah E, Kleschevnikov AM, Villar AJ, Epstein CJ, Salehi A, et al. Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. J Comp Neurol 2004 Dec. 13;480(3):281-98. PMID: 15515178
31. Faizi M, Bader PL, Tun C, Encarnacion A, Kleschevnikov A, Belichenko P, et al. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of beta1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol Dis 2011 Aug; 43(2):397-413. doi: 10.1016/j.nbd.2011.04.011 PMID: 21527343
32. Kleschevnikov AM, Belichenko PV, Faizi M, Jacobs LF, Htun K, Shamloo M, et al. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J Neurosci 2012 Jul. 4;32(27):9217-27. doi: 10.1523/JNEUROSCI.1673-12.2012 PMID: 22764230
33. Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS, et al. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 2006 Jul. 6;51(1):29-42. PMID: 16815330
34. Salehi A, Faizi M, Colas D, Valletta J, Laguna J, Takimoto-Kimura R, et al. Restoration of norepinephrinemodulated contextual memory in a mouse model of Down syndrome. Sci Transl Med 2009 Nov. 18;1(7):7ra17. doi: 10.1126/scitranslmed.3000258 PMID: 20368182
35. Muhs A, Hickman DT, Pihlgren M, Chuard N, Giriens V, Meerschman C, et al. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A 2007 Jun. 5;104(23):9810-5. PMID: 17517595
36. Bowes C, Li T, Frankel WN, Danciger M, Coffin JM, Applebury ML, et al. Localization of a retroviral element within the rd gene coding for the beta subunit of cGMP phosphodiesterase. Proc Natl Acad Sci U S A 1993 Apr. 1;90(7):2955-9. PMID: 8385352
37. Belichenko PV, Kleschevnikov AM, Masliah E, Wu C, Takimoto-Kimura R, Salehi A, et al. Excitatoryinhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome. J Comp Neurol 2009 Feb. 1;512(4):453-66. doi: 10.1002/cne.21895 PMID: 19034952
38. Jankowsky JL, Younkin LH, Gonzales V, Fadale DJ, Slunt HH, Lester HA, et al. Rodent Abeta modulates the solubility and distribution of amyloid deposits in transgenic mice. J Biol Chem 2007 Jun. 7;3(282 (31)):22707-20.
39. Shankar GM, Welzel AT, McDonald JM, Selkoe DJ, Walsh DM. Isolation of low-n amyloid beta-protein oligomers from cultured cells, CSF, and brain. Methods Mol Biol 2011;670:33-44. doi: 10.1007/978-1-60761-744-0-3 PMID: 20967581
40. Weissmiller AM, Natera-Naranjo O, Reyna SM, Pearn ML, Zhao X, Nguyen P, et al. A gamma-secretase inhibitor, but not a gamma-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP. PLoS ONE 2015;10(2):e0118379. doi: 10.1371/journal.pone. 0118379 PMID: 25710492
41. Zhang K, Fishel Ben KR, Osakada Y, Xu W, Sinit RS, Chen L, et al. Defective axonal transport of Rab7 GTPase results in dysregulated trophic signaling. J Neurosci 2013 Apr. 24;33(17):7451-62. doi: 10. 1523/JNEUROSCI.4322-12.2013 PMID: 23616551
42. Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A 1976 Jul; 73(7):2424-8. PMID: 1065897
43. Kounnas MZ, Morris RE, Thompson MR, Fitz Gerald DJ, Strickland DK, Saelinger CB. The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem 1992 Jun. 25;267(18):12420-3. PMID: 1618748
44. Belichenko PV, Kleschevnikov AM, Becker A, Wagner GE, Lysenko LV, Yu YE, et al. Down Syndrome Cognitive Phenotypes Modeled in Mice Trisomic for All HSA 21 Homologues. PLoS ONE 2015;10(7):e0134861. doi: 10.1371/journal.pone.0134861 PMID: 26230397
45. Belichenko NP, Belichenko PV, Kleschevnikov AM, Salehi A, Reeves RH, Mobley WC. The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J Neurosci 2009 May 6;29(18):5938-48. doi: 10.1523/JNEUROSCI.1547-09.2009 PMID: 19420260
46. Emy PY, Levin TL, Sheth SS, Ruzal-Shapiro C, Garvin J, Berdon WE. Iron overload in reticuloendothelial systems of pediatric oncology patients who have undergone transfusions: MR observations. AJR Am J Roentgenol 1997 Apr; 168(4):1011-5. PMID: 9124106
47. Akwa Y, Hassett DE, Eloranta ML, Sandberg K, Masliah E, Powell H, et al. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol 1998 Nov. 1;161(9):5016-26. PMID: 9794439
48. Cooper JD, Salehi A, Delcroix JD, Howe CL, Belichenko PV, Chua-Couzens J, et al. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci U S A 2001 Aug. 28;98(18):10439-44. PMID: 11504920
49. Seabrook TJ, Thomas K, Jiang L, Bloom J, Spooner E, Maier M, et al. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol Aging 2007 Jun; 28(6):813-23. PMID: 16725229
50. Gardiner KJ. Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations. Drug Des Devel Ther 2015;9:103-25. doi: 10.2147/DDDT. S51476 PMID: 25552901
51. Karran E, Mercken M, Strooper BD. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011;10(9):698-712. doi: 10. 1038/nrd3505 PMID: 21852788
52. Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL. Immune hyporesponsiveness to amyloid betapeptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci U S A 2001 Aug. 28;98(18):10273-8. PMID: 11517335
53. Ugazio AG, Maccario R, Notarangelo LD, Burgio GR. Immunology of Down syndrome: a review. Am J Med Genet Suppl 1990;7:204-12. PMID: 2149949
54. Trotta MB, Serro Azul JB, Wajngarten M, Fonseca SG, Goldberg AC, Kalil JE. Inflammatory and Immunological parameters in adults with Down syndrome. Immun Ageing 2011;8(1):4. doi: 10.1186/1742-4933-8-4 PMID: 21496308
55. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005 May 10;64(9):1553-62. PMID: 15883316
56. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003 Jul. 8;61(1):46-54. PMID: 12847155
57. Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004 Jan; 14(1):11-20. PMID: 14997933
58. Pihlgren M, Silva AB, Madani R, Giriens V, Waeckerle-Men Y, Fettelschoss A, et al. TLR4 and TRIFdependent stimulation of B lymphocytes by peptide liposomes enables T-cell independent isotype switch in mice. Blood 2013 Jan 3;121(1):85-94. doi: 10.1182/blood-2012-02-413831 PMID: 23144170
59. Sigurdsson EM, Wisniewski T, Frangione B. A safer vaccine for Alzheimer's disease? Neurobiol Aging 2002 Nov; 23(6):1001-8. PMID: 12470795